{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:39:58Z","timestamp":1773056398468,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["R01EY036417"],"award-info":[{"award-number":["R01EY036417"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["R01EY027749"],"award-info":[{"award-number":["R01EY027749"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["R24EY028764"],"award-info":[{"award-number":["R24EY028764"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["R21EY035421"],"award-info":[{"award-number":["R21EY035421"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["R44EY027665"],"award-info":[{"award-number":["R44EY027665"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["R43EY032827"],"award-info":[{"award-number":["R43EY032827"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-025-01732-4","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T17:02:27Z","timestamp":1750006947000},"page":"1313-1321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Age-independent anti-angiogenic therapy for choroidal neovascularization by targeting secretogranin III"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4543-6751","authenticated-orcid":false,"given":"Chengchi","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1715-6362","authenticated-orcid":false,"given":"Hong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9566-8764","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"key":"1732_CR1","doi-asserted-by":"publisher","first-page":"1411278","DOI":"10.3389\/fmed.2024.1411278","volume":"11","author":"S Cheng","year":"2024","unstructured":"Cheng S, Zhang S, Huang M, et al. Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications. Front Med (Lausanne). 2024;11:1411278.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1732_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21(1):133.","journal-title":"J Transl Med"},{"key":"1732_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW. Incomplete response to anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82: 100906.","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"1732_CR4","first-page":"1532","volume":"36","author":"T Empeslidis","year":"2019","unstructured":"Empeslidis T, Storey M, Giannopoulos T, et al. How successful is switching from bevacizumab or ranibizumab to aflibercept in age-related macular degeneration? A systematic overview Adv Ther. 2019;36(7):1532\u201348.","journal-title":"A systematic overview Adv Ther"},{"issue":"1","key":"1732_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s42003-020-1113-z","volume":"3","author":"L Zhu","year":"2020","unstructured":"Zhu L, Parker M, Enemchukwu N, et al. Combination of apolipoprotein-A-I\/apolipoprotein-A-I binding protein and anti-VEGF treatment overcomes anti-VEGF resistance in choroidal neovascularization in mice. Commun Biol. 2020;3(1):386.","journal-title":"Commun Biol"},{"key":"1732_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2022.109215","volume":"223","author":"VP Nguyen","year":"2022","unstructured":"Nguyen VP, Henry J, Zhe J, et al. Age differential response to bevacizumab therapy in choroidal neovascularization in rabbits. Exp Eye Res. 2022;223: 109215.","journal-title":"Exp Eye Res"},{"issue":"12","key":"1732_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.63.12.2","volume":"63","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Shen MM, Fu Y. Combination of AIBP, apoA-I, and aflibercept overcomes anti-VEGF resistance in neovascular AMD by inhibiting arteriolar choroidal neovascularization. Invest Ophthalmol Vis Sci. 2022;63(12):2.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1732_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1084\/jem.20161802","volume":"214","author":"ME LeBlanc","year":"2017","unstructured":"LeBlanc ME, Wang W, Chen X, et al. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. J Exp Med. 2017;214(4):1029\u201347.","journal-title":"J Exp Med"},{"issue":"12","key":"1732_CR9","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1111\/febs.16356","volume":"289","author":"L Ji","year":"2022","unstructured":"Ji L, Waduge P, Wan W, et al. Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization. FEBS J. 2022;289(12):3521\u201334.","journal-title":"FEBS J"},{"issue":"1","key":"1732_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00018-021-04111-2","volume":"79","author":"C Dai","year":"2022","unstructured":"Dai C, Waduge P, Ji L, et al. Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy. Cell Mol Life Sci. 2022;79(1):63.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1732_CR11","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101085RR","volume":"36","author":"L Ji","year":"2022","unstructured":"Ji L, Waduge P, Hao L, et al. Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization. FASEB J. 2022;36(1): e22106.","journal-title":"FASEB J"},{"issue":"13","key":"1732_CR12","doi-asserted-by":"publisher","first-page":"10531","DOI":"10.3390\/ijms241310531","volume":"24","author":"L Ji","year":"2023","unstructured":"Ji L, Waduge P, Wu Y, et al. Secretogranin III selectively promotes vascular leakage in the deep vascular plexus of diabetic retinopathy. Int J Mol Sci. 2023;24(13):10531.","journal-title":"Int J Mol Sci"},{"key":"1732_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.exer.2019.01.009","volume":"181","author":"ME LeBlanc","year":"2019","unstructured":"LeBlanc ME, Wang W, Ji Y, et al. Secretogranin III as a novel target for the therapy of choroidal neovascularization. Exp Eye Res. 2019;181:120\u20136.","journal-title":"Exp Eye Res"},{"issue":"3","key":"1732_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10456-019-09662-4","volume":"22","author":"F Tang","year":"2019","unstructured":"Tang F, LeBlanc ME, Wang W, et al. Anti-Secretogranin III therapy of oxygen-induced retinopathy with optimal safety. Angiogenesis. 2019;22(3):369\u201382.","journal-title":"Angiogenesis"},{"issue":"1","key":"1732_CR15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/ijms23010350","volume":"23","author":"Y He","year":"2021","unstructured":"He Y, Tian H, Dai C, et al. Optimal efficacy and safety of humanized anti-Scg3 antibody to alleviate oxygen-induced retinopathy. Int J Mol Sci. 2021;23(1):350.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"1732_CR16","doi-asserted-by":"publisher","first-page":"9507","DOI":"10.3390\/ijms25179507","volume":"25","author":"C Huang","year":"2024","unstructured":"Huang C, Waduge P, Kaur A, et al. Optimal humanized Scg3-neutralizing antibodies for anti-angiogenic therapy of diabetic retinopathy. Int J Mol Sci. 2024;25(17):9507.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1732_CR17","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.3390\/biomedicines11071910","volume":"11","author":"C Huang","year":"2023","unstructured":"Huang C, Ji L, Kaur A, et al. Anti-Scg3 gene therapy to treat choroidal neovascularization in mice. Biomedicines. 2023;11(7):1910.","journal-title":"Biomedicines"},{"issue":"2","key":"1732_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","volume":"161","author":"N Ferrara","year":"1989","unstructured":"Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4\u20135","key":"1732_CR19","first-page":"383","volume":"55","author":"N Ferrara","year":"2011","unstructured":"Ferrara N. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. Int J Dev Biol. 2011;55(4\u20135):383\u20138.","journal-title":"Int J Dev Biol"},{"key":"1732_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev-cellbio-092910-154002","volume":"27","author":"AS Chung","year":"2011","unstructured":"Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011;27:563\u201384.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"11","key":"1732_CR21","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/blood-2012-04-396846","volume":"120","author":"P Sapieha","year":"2012","unstructured":"Sapieha P. Eyeing central neurons in vascular growth and reparative angiogenesis. Blood. 2012;120(11):2182\u201394.","journal-title":"Blood"},{"issue":"12","key":"1732_CR22","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1039\/c3ib40085a","volume":"5","author":"F Milde","year":"2013","unstructured":"Milde F, Lauw S, Koumoutsakos P, Iruela-Arispe ML. The mouse retina in 3D: quantification of vascular growth and remodeling. Integr Biol (Camb). 2013;5(12):1426\u201338.","journal-title":"Integr Biol (Camb)"},{"issue":"6554","key":"1732_CR23","doi-asserted-by":"publisher","first-page":"eabc8479","DOI":"10.1126\/science.abc8479","volume":"373","author":"M Grunewald","year":"2021","unstructured":"Grunewald M, Kumar S, Sharife H, et al. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. Science. 2021;373(6554):eabc8479.","journal-title":"Science"},{"issue":"11","key":"1732_CR24","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","volume":"24","author":"L P\u00e9rez-Guti\u00e9rrez","year":"2023","unstructured":"P\u00e9rez-Guti\u00e9rrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol. 2023;24(11):816\u201334.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"1732_CR25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.exger.2004.06.003","volume":"39","author":"P Picciotti","year":"2004","unstructured":"Picciotti P, Torsello A, Wolf FI, Paludetti G, Gaetani E, Pola R. Age-dependent modifications of expression level of VEGF and its receptors in the inner ear. Exp Gerontol. 2004;39(8):1253\u20138.","journal-title":"Exp Gerontol"},{"issue":"4","key":"1732_CR26","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.3390\/ijms24043318","volume":"24","author":"V Di Nisio","year":"2023","unstructured":"Di Nisio V, Rossi G, Chiominto A, Pompili E, Cecconi S. Do aging and parity affect VEGF-A\/VEGFR content and signaling in the ovary?-A mouse model study. Int J Mol Sci. 2023;24(4):3318.","journal-title":"Int J Mol Sci"},{"issue":"22","key":"1732_CR27","doi-asserted-by":"publisher","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","volume":"90","author":"RL Kendall","year":"1993","unstructured":"Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993;90(22):10705\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1732_CR28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1091\/mbc.e02-07-0379","volume":"14","author":"L Labrecque","year":"2003","unstructured":"Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, B\u00e9liveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell. 2003;14(1):334\u201347.","journal-title":"Mol Biol Cell"},{"issue":"3","key":"1732_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/biom14030252","volume":"14","author":"Y Fu","year":"2024","unstructured":"Fu Y, Zhang Z, Webster KA, Paulus YM. Treatment strategies for anti-VEGF resistance in neovascular age-related macular degeneration by targeting arteriolar choroidal neovascularization. Biomolecules. 2024;14(3):252.","journal-title":"Biomolecules"},{"issue":"11","key":"1732_CR30","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.2337\/diabetes.48.11.2229","volume":"48","author":"ME Cooper","year":"1999","unstructured":"Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999;48(11):2229\u201339.","journal-title":"Diabetes"},{"key":"1732_CR31","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/srep01932","volume":"3","author":"G Egawa","year":"2013","unstructured":"Egawa G, Nakamizo S, Natsuaki Y, Doi H, Miyachi Y, Kabashima K. Intravital analysis of vascular permeability in mice using two-photon microscopy. Sci Rep. 2013;3:1932.","journal-title":"Sci Rep"},{"issue":"2","key":"1732_CR32","first-page":"114","volume":"5","author":"R Oakley","year":"2014","unstructured":"Oakley R, Tharakan B. Vascular hyperpermeability and aging. Aging Dis. 2014;5(2):114\u201325.","journal-title":"Aging Dis"},{"key":"1732_CR33","doi-asserted-by":"crossref","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Writing Committee, Martin DF, Maguire, MG, et al. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: Two-Year Results. Ophthalmology. 2020;127(4S):S135\u2013S145.","DOI":"10.1016\/j.ophtha.2020.01.029"},{"issue":"12","key":"1732_CR34","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"2","key":"1732_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Roger","year":"2010","unstructured":"Roger S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-319.e1.","journal-title":"Ophthalmology"},{"issue":"2","key":"1732_CR36","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.oret.2021.05.004","volume":"6","author":"Y Li","year":"2022","unstructured":"Li Y, Hall NE, Pershing S, et al. Age, gender, and laterality of retinal vascular occlusion: a retrospective study from the IRIS\u00ae Registry. Ophthalmol Retina. 2022;6(2):161\u201371.","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"1732_CR37","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.oret.2021.02.008","volume":"5","author":"P Sen","year":"2021","unstructured":"Sen P, Gurudas S, Ramu J, et al. Predictors of visual acuity outcomes after anti-vascular endothelial growth factor treatment for macular edema secondary to central retinal vein occlusion. Ophthalmol Retina. 2021;5(11):1115\u201324.","journal-title":"Ophthalmol Retina"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01732-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01732-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01732-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:24:02Z","timestamp":1773048242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01732-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1732"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01732-4","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,15]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HT and WL are shareholders of Everglades Biopharma, LLC and LigandomicsRx, LLC. WL is an inventor of issued and pending patents. CH declares no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}